ERBB2 and neoplasm: They compared the predictive value of two commercially available techniques used for CTC counting: the CellSearch system with the AdnaTest BreastCancer system, which is based on the detection of three tumor-associated transcripts by reverse transcription-polymerase chain reaction (RT- PCR) in metastatic breast cancer patients, especially in those with the HER2+ subtype.